Clinical efficacy and safety of intravenous itraconazole in the management of invasive candidiasis in patients of surgery and critical care

Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy
Yoshio TakesueNaoki Aikawa

Abstract

Although itraconazole exhibits potent activity against Candida species, there have been few studies examining the use of intravenous itraconazole in the treatment of invasive candidiasis. A nationwide multicenter clinical study was conducted to evaluate the efficacy and safety of intravenous itraconazole in the management of invasive candidiasis, including non-albicans Candida species, in non-neutropenic patients undergoing surgery and critical care. Between September 2007 and August 2009, patients with proven and presumed candidiasis were enrolled at 22 participating institutions. Patients with presumed candidiasis had a deep-body temperature of 37.8°C or higher and were positive for serum β-D: -glucan or two or more colonization sites of Candida species. The main exclusion criterion was severe renal impairment (creatinine clearance <30 ml/min). The primary efficacy analysis was based on clinical and microbiological responses 5-10 days after the end of treatment, assessed by an independent data review committee. Of the 60 patients enrolled, 49 were included in the modified intention-to-treat population; 31 patients received a definitive diagnosis and 18 patients a presumed diagnosis. Intravenous itraconazole was used as first-...Continue Reading

References

Mar 18, 2000·Journal of Chemotherapy·T F Patterson
Aug 13, 2002·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·W E TrickUNKNOWN National Nosocomial Infections Surveillance System Hospitals
Oct 10, 2002·Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy·Naoki AikawaYoji Yamazaki
Dec 20, 2002·The New England Journal of Medicine·Jorge Mora-DuarteUNKNOWN Caspofungin Invasive Candidiasis Study Group
Nov 20, 2004·Nihon Ishinkin Gakkai zasshi = Japanese journal of medical mycology·Minoru Yoshida
Jun 20, 2007·The Journal of Antimicrobial Chemotherapy·Michael D ParkinsKevin B Laupland
Dec 18, 2007·The Journal of Infection·Graeme N ForrestJennifer K Johnson
Feb 5, 2009·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Peter G PappasUNKNOWN Infectious Diseases Society of America
Jul 23, 2009·The Journal of Antimicrobial Chemotherapy·Matteo BassettiClaudio Viscoli
Aug 19, 2009·Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy·Naoki AikawaHideharu Tanaka

❮ Previous
Next ❯

Citations

Feb 7, 2016·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·M C ArendrupUNKNOWN Subcommittee on Antifungal Susceptibility Testing (AFST) of the ESCMID European Committee for Antimicrobial Susceptibility T
Jun 12, 2013·Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy·Dionyssia-Pinelopi CarrerEvangelos J Giamarellos-Bourboulis

❮ Previous
Next ❯

Related Concepts

Related Feeds

Candida albicans

Candida albicans is an opportunistic, fungal pathogen of humans that frequently causes superficial infections of oral and vaginal mucosal surfaces of debilitated and susceptible individuals. Discover the latest research on Candida albicans here.

Candidiasis

Candidiasis is a common fungal infection caused by Candida and it can affect many parts for the body including mucosal membranes as well as the gastrointestinal, urinary, and respiratory tracts. Here is the latest research.

Candidiasis (ASM)

Candidiasis is a common fungal infection caused by Candida and it can affect many parts for the body including mucosal membranes as well as the gastrointestinal, urinary, and respiratory tracts. Here is the latest research.